NCT07192614 - A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

April 2, 2029

Study Completion Date

April 2, 2029

Conditions

Prostate Cancer

Interventions

DRUG

AZD6621

A T Cell-engaging Antibody that targets STEAP2, CD3, and CD8

Trial Locations (13)

5505

RECRUITING

Research Site, Seoul

11725

NOT_YET_RECRUITING

Research Site, Commack

33612

NOT_YET_RECRUITING

Research Site, Tampa

49546

RECRUITING

Research Site, Grand Rapids

100142

NOT_YET_RECRUITING

Research Site, Beijing

510060

NOT_YET_RECRUITING

Research Site, Guangzhou

2100008

NOT_YET_RECRUITING

Research Site, Nanjing

02114

WITHDRAWN

Research Site, Boston

02903

NOT_YET_RECRUITING

Research Site, Providence

104-0045

NOT_YET_RECRUITING

Research Site, Chūōku

573-1191

NOT_YET_RECRUITING

Research Site, Hirakata-shi

277-8577

NOT_YET_RECRUITING

Research Site, Kashiwa

03080

NOT_YET_RECRUITING

Research Site, Seoul